The therapy of chronic lymphocytic leukemia (CLL) is in an era of momentous change from chemotherapy towards targeted therapy. The first phase was the introduction of monoclonal antibodies, especially the anti-CD20 antibodies rituximab, ofatumumab, and obinutuzumab in combination immunochemotherapy. More recently, small molecular inhibitors have emerged which target the B-cell receptor signaling pathways (ibrutinib and idelalisib), BCL-2 (ABT-199), and immunomodulation [immunomodulatory drugs (IMiDs), lenalidomide]. In this rapidly changing landscape, what is the role of the anti-CD20 monoclonal antibody ofatumumab in CLL?
Jan A. Burger, Kelvin W. Li, Michael J. Keating, Mariela Sivina, Ahmed M. Amer, Naveen Garg, Alessandra Ferrajoli, Xuelin Huang, Hagop Kantarjian, William G. Wierda, Susan O’Brien, Marc Hellerstein, Scott Turner, Claire Emson, Shih‐Shih Chen, Xiao‐Jie Yan, Dominik Wodarz, Nicholas Chiorazzi
Franca Raucci, Claudio Vernieri, Maira Di Tano, Francesca Ligorio, Olga Blaževitš, Samuel Lazzeri, Anastasiya Shmahala, Giuseppe Fragale, Giulia Salvadori, Gabriele Varano, Stefano Casola, Roberta Buono, Euplio Visco, Filippo de Braud, Valter D. Longo
Discussion(0)
No comments yet. Be the first to comment.